Mesa and Ulmer Measure Methods for JAK Inhibitor Optimization in Myelofibrosis

Season 4, Episode 7,  Nov 19, 2020, 10:03 PM

In our exclusive interview, Dr. Mesa and Dr. Ulmer discuss the current roles of ruxolitinib and fedratinib in myelofibrosis, current guidance for JAK inhibitor dosing, the utility of re-exposure to JAK inhibitors, and clinical trial options.